General information about HMG in the UK
lyophilisates for solution for intramuscular injection
Hypersensitivity, tumors of the hypothalamic-pituitary region, hyperprolactinemia, adrenal and thyroid disease;
for women - persistent enlargement of the ovaries, ovarian cyst (not due to the presence of polycystic ovary syndrome), polycystic ovary syndrome, abnormal development of reproductive organs (incompatible with normal pregnancy), uterine fibroids, metrorrhagia (unknown etiology), estrogen-dependent tumors (ovarian cancer uterine cancer, breast cancer), primary ovarian failure, pregnancy, lactation;
for men - prostate cancer, testicular tumor, tumor androgen.
Dosage and administration:
V / m and s / c, a solution is prepared immediately prior to injection with the supplied solvent. 1 ml of the solvent, dissolve the contents of five vials. To stimulate the growth of the dominant follicle in women using two different dosing regimens.
The first scheme: daily administration at a dose of 75 IU within the first 7 days of the cycle in menstruating women. Injections continued until adequate response is achieved, to judge the occurrence of which can be on the daily analysis of the concentration of estrogen and determining the size of the follicles using ultrasound. The maturation of the follicles usually occurs during a treatment cycle lasting 7-12 days. In the absence of ovarian response on administration a daily dose can be gradually increased to 150 IU.
The second scheme: the introduction of a day for 1 week. The initial dose is 225-375 IU / day. If adequate stimulation is not achieved, the dose can be gradually increased.
After treatment for any of the schemes and in the presence of an adequate, but not excessive ovarian response, determined on the basis of clinical and biochemical studies, 24-48 hours after the last administration menotropina, to induce ovulation is administered once 5-10 thousand IU of human CG enhancing the content of LH and stimulates the release of a mature egg.
In the presence of absence of ovulation and pregnancy treatment may be repeated for any of the schemes for 2 cycles. On the day of hCG administration and the next 2-3 days the patient is recommended to have sexual intercourse. Upon stimulation "superovulation" (during assisted reproductive techniques) the duration of administration of the drug may be greater.
Use in men: for hypogonadotropic hypogonadism in men to stimulate spermatogenesis drug is given, if the earlier treatment of human androgen hCG caused a reaction with no signs of strengthening of spermatogenesis.
In this case, the treatment is continued by introducing two thousand IU hCG human 2 times per week together with injections menotropina 75 IU three times a week. Treatment of this scheme should continue for at least 4 months, continued treatment with inefficiency by introducing human thousand IU hCG to 2 2 times a week, and 150 IU menotropina 3 times a week.
Status of spermatogenesis should be assessed on a monthly basis, and in the absence of positive results over the next 3 months of treatment should be discontinued. When idiopathic oligospermia normogonadotropic introduced weekly 5 thousand IU hCG human s / c or i / m, with a parallel introduction of 75-150 IU menotropina 3 times a week for 3 months.
To stimulate spermatogenesis - 1-3 thousand IU hCG three times per week to normalize the concentration of testosterone in the blood. Thereafter, for several months three times a week - menotropina 75-150 IU.